The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Richard Ramanius - Redeye AB - Analyst
: Hello and good afternoon. I have two sets of questions. The first one is about the CEO change and also -- and this ties in, I guess, with transaction
and business development. So my question is the CEO change related to what I see as the need to close at least one transaction with one of your
projects, one of your programs, CAN10 or CAN04 in this year?
And as a follow-up to that, where do you see the most interest in oncology or immunology and how important will the triple negative breast cancer
results with CAN04 be for potential licensing discussions?
Question: Richard Ramanius - Redeye AB - Analyst
: Yeah, thank you. Yeah, that's good enough.
Question: Richard Ramanius - Redeye AB - Analyst
: Okay, understand. My next series of questions regard indication HS. Well, I have two questions on that just to understand a bit better the market
size. You mentioned around 50% to each -- was IL-17 and the Humira. So what -- how should we interpret that to mean in terms of total patients
that do not respond? Is that -- would that be like 50% respond to Humira and you got 50% -- 50% respond to anti-IL-17, does that mean about 25%
of the market remains, so I guess it's more than that.
Question: Richard Ramanius - Redeye AB - Analyst
: I think you almost answered my last question. You mentioned Stage 3, but would you -- does that mean you would also enroll Stage 1 patients?
Question: Richard Ramanius - Redeye AB - Analyst
: Would you treat patients in just Stage 1 HS?
Question: Richard Ramanius - Redeye AB - Analyst
: I mean, Stage 1 through Stage 3.
Question: Richard Ramanius - Redeye AB - Analyst
: Okay, thanks. That's -- you've answered all the questions I have.
Question: Luisa Morgado - Van Lanschot Kempen N.V. - Analyst
: Hi, Team. Thank you for taking my question. And of course, congrats, Damian, for the new role. Maybe just to start out, as you mentioned, you will
now be a bit more focused in regards to being able to achieve any kind of structure like a transaction this year. Could you elaborate a bit in terms
of -- if anything is changing in the strategy and also prioritizing other -- in terms of prioritizing stuff in the pipeline?
Question: Luisa Morgado - Van Lanschot Kempen N.V. - Analyst
: Thank you. That's quite clear. And in terms of the AML study, could you elaborate a bit more on the timelines, but also if you already have any, of
course, aspects in trial design that you can advance?
Question: Luisa Morgado - Van Lanschot Kempen N.V. - Analyst
: Okay. Thank you. And maybe just one final question. Maybe for Patrik, what can we expect in terms of expenses for this year? Will the level be
maintained or will we see, of course, an increase with the Phase 2 start with CAN10 and of course, also dependent on CANFOUR eventually, potentially
starting?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
FEBRUARY 21, 2025 / 2:00PM, CANTA.ST - Q4 2024 Cantargia AB Earnings Call
Question: Luisa Morgado - Van Lanschot Kempen N.V. - Analyst
: Okay, that's quite helpful.
Question: Luisa Morgado - Van Lanschot Kempen N.V. - Analyst
: Yeah, quite helpful. Thank you so much.
| 
